ADC Therapeutics (ADCT) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares.
View ADCT analyst ratings or view top-rated stocks.

6 brokerages have issued 1-year price objectives for ADC Therapeutics' stock. Their ADCT share price forecasts range from $2.00 to $12.00. On average, they anticipate the company's share price to reach $8.20 in the next year. This suggests a possible upside of 914.2% from the stock's current price.
View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts.

ADC Therapeutics' stock was trading at $3.84 at the beginning of 2023. Since then, ADCT stock has decreased by 78.9% and is now trading at $0.8085.
View the best growth stocks for 2023 here.

ADC Therapeutics saw a decline in short interest in August. As of August 15th, there was short interest totaling 5,320,000 shares, a decline of 13.6% from the July 31st total of 6,160,000 shares. Based on an average daily volume of 461,400 shares, the days-to-cover ratio is presently 11.5 days. Currently, 8.5% of the shares of the stock are sold short.
View ADC Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ADCT earnings forecast.

ADC Therapeutics SA (NYSE:ADCT) released its earnings results on Tuesday, August, 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.14. The business earned $19.28 million during the quarter, compared to analyst estimates of $34.77 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 325.79% and a negative net margin of 98.33%.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

(ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

ADC Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "ADCT."

ADC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Prosight Management LP (7.27%), JPMorgan Chase & Co. (3.59%), Goldman Sachs Group Inc. (1.48%), Vantage Consulting Group Inc (1.15%), AlphaCentric Advisors LLC (1.01%) and BlackRock Inc. (0.61%).

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADCT stock can currently be purchased for approximately $0.81.

ADC Therapeutics (NYSE:ADCT) has a market capitalization of $62.10 million and generates $184.39 million in revenue each year. The company earns $-155,800,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis.

The company employs 317 workers across the globe.

The official website for the company is www.adctherapeutics.com. The company can be reached via phone at 41-21-653-0200 or via email at amanda.hamilton@adctherapeutics.com.